PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
Status:
RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial designed to evaluate the efficacy and safety of PCSK9 inhibitor combined with statin therapy compared to statin monotherapy in reversing asymptomatic intracranial atherosclerosis, assessed using high-resolution magnetic resonance imaging of the intracranial vessel walls.
Phase:
PHASE4
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Baotou Central Hospital Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine Chinese PLA General Hospital Chongqing General Hospital First Affiliated Hospital of Harbin Medical University Hebei General Hospital Huashan Hospital Jining First People's Hospital Liaocheng People's Hospital Nanjing First Hospital, Nanjing Medical University Taihe Hospital Tangshan Worker's Hospital The Affiliated Hospital of Qingdao University The First Affiliated Hospital of Zhengzhou University Weifang People's Hospital Zhongnan Hospital